Literature DB >> 21686965

Post-transplant lymphoproliferative disorder in an adolescent masquerading as a complicated primary EBV infection.

Heather L Henry1, Conrad Vincent Fernandez, Gerard Corsten.   

Abstract

This report describes an adolescent girl with primary Epstein-Barr virus (EBV) infection in the setting of intensive immunosuppression for a cardiac transplant. She went on to develop progressive pain, weight loss and night sweats with necrosis of the tonsils over 8 weeks. The clinical impression was initially that of a complicated tonsillitis secondary to immune dysfunction. Biopsy 2 months after first presentation demonstrated diffuse B cell lymphoma consistent with post-transplant lymphoproliferative disorder (PTLD). We present this case to highlight the need for a high degree of clinical suspicion for PTLD in a population of patients who commonly experience primary exposure to EBV.

Entities:  

Year:  2009        PMID: 21686965      PMCID: PMC3028415          DOI: 10.1136/bcr.04.2009.1758

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.

Authors:  N D Zilz; L J Olson; C G McGregor
Journal:  J Heart Lung Transplant       Date:  2001-07       Impact factor: 10.247

2.  Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry.

Authors:  Meredith J Aull; Joseph F Buell; Jennifer Trofe; M Roy First; Rita R Alloway; Michael J Hanaway; Lynne Wagoner; Thomas G Gross; Thomas Beebe; E Steve Woodle
Journal:  Transplantation       Date:  2004-12-15       Impact factor: 4.939

3.  Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant.

Authors:  G Dotti; A Rambaldi; R Fiocchi; T Motta; G Torre; P Viero; B Gridelli; T Barbui
Journal:  Haematologica       Date:  2001-06       Impact factor: 9.941

4.  Cyclosphosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease.

Authors:  I C Balfour; D Wall; A Luisiri; C Sotelo; T G Gross
Journal:  J Heart Lung Transplant       Date:  1999-05       Impact factor: 10.247

5.  Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.

Authors:  Marie Odile Serinet; Emmanuel Jacquemin; Dalila Habes; Dominique Debray; Monique Fabre; Olivier Bernard
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-04       Impact factor: 2.839

6.  Utility of head and neck biopsies in the evaluation of posttransplant lymphoproliferative disorder.

Authors:  Paolo Campisi; Upton D Allen; Bo-Yee Ngan; Michael Hawkes; Vito Forte
Journal:  Otolaryngol Head Neck Surg       Date:  2007-08       Impact factor: 3.497

Review 7.  Posttransplant lymphoproliferative disorder.

Authors:  Matthew J Everly; Roy D Bloom; Donald E Tsai; Jennifer Trofe
Journal:  Ann Pharmacother       Date:  2007-10-16       Impact factor: 3.154

8.  Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.

Authors:  S Schubert; H Abdul-Khaliq; H B Lehmkuhl; M Yegitbasi; P Reinke; C Kebelmann-Betzig; K Hauptmann; U Gross-Wieltsch; R Hetzer; F Berger
Journal:  Pediatr Transplant       Date:  2008-06-01

9.  An unusual presentation of post-transplant lymphoproliferative disorder mimicking vasculitis in heart transplantation.

Authors:  David L Murray; Naveen L Pereira; Dylan V Miller
Journal:  J Heart Lung Transplant       Date:  2008-11       Impact factor: 10.247

10.  Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients.

Authors:  T Sato; M Fujieda; A Maeda; E Tanaka; M Miyamura; H Chikamoto; M Hisano; Y Akioka; Y Ishiura; S Dohno; M Hattori; H Wakiguchi
Journal:  Clin Nephrol       Date:  2008-11       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.